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An Easily Forgiven “Latecomer”We are thankful to De Rosa and colleagues for their additional
analysis of, and insight into the topic covered in our report (1).
Although we were unable to directly replicate their ﬁndings, their
ﬁndings are interesting and hypothesis generating. It is conceivable
that aspiration thrombectomy will have a U-shaped relationship with
ischemic time when more trials are included. With longer ischemic
times, the thrombus becomes more organized and is subsequently
harder to retrieve with manual aspiration catheters. This hypothesis
should be actively investigated in future studies on this topic.*Dharam J. Kumbhani, MD, SM
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No Magic Remedies
Cardiovascular (CV) prevention has long been a target of clinical trials
in diabetes mellitus (DM). Several of those trials, however, have been
unsuccessful. In an effort to address this issue, the recently published
PONTIAC(NT-proBNPGuidedPrimaryPrevention ofCVEvents
in Diabetic Patients) trial used natriuretic peptides (NPs) to select
patients who had a relatively greater need for CV prevention and
hence were probably more prone to improvement (1). This study was
successful, but there were some questions that arise from this and
previous trials on CV prevention in DM.
First, was the poor patient selection the main reason why the
previous trials failed? The interventions used by some of the pre-
vious trials also may have not been successful. For example, in the
ROADMAP (Randomized Olmesartan and Diabetes Micro-
albuminuria Prevention) trial, a high dose of an effective angiotensin
receptor inhibitor (20 mg olmesartan) was used to prevent micro-
albuminuria in patients with DM who did not have hypertension,
which resulted in high rates of hypotension and other complications
and thus treatment failure (2,3). In the PONTIAC trial, a small but
signiﬁcant decline in estimated glomerular ﬁltration rate observed in
the intensiﬁed treatment group may be of some concern.
Second, what is the underlying pathophysiology for a mild in-
crease in NP levels in symptomatic patients with DM but without
known cardiac disease? There are several reasons for false-positive
or negative NP results, particularly in a population such as those
with DM, characterized by increased rates of comorbidities such as
renal dysfunction or obesity. In other words, what is the patho-
genetic process that we treat in those patients, and is the neuro-
hormonal blockage a suitable treatment for this process? In the
PONTIAC trial, there was no signiﬁcant reduction in NP levels in
the intensiﬁed treatment group during the study period, and thus
the reason for elevated levels of NP at baseline was probably not
addressed by the applied intervention.
Third, how should we titrate and monitor neurohormonal
blockade therapy in patients without a clear evidence-based indica-
tion for such a therapy, such as arterial hypertension or heart failure?
In the PONTIAC trial, treatment titration could not have been
guided or followed by NPs, because there was no signiﬁcant differ-
ence in NP levels between the 2 study groups at the end of the study.
Finally, could the positive results of the PONTIAC trial be
explained solely by the increased use of health care resources in
the intensiﬁed treatment group? Those patients were seen regu-
larly not only by diabetologists but also by cardiologists in the
cardiac outpatient clinics where they were receiving individu-
alized treatment, and that may be a sufﬁcient reason for a better
outcome. In other words, the success of the PONTIAC trial may
not lie on the use of NPs for patient selection but instead on the
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2054intensiﬁcation and individualization of their cardiac care. The
ﬁnding that event rates were similarly low in the intensiﬁed group
and in patients who had low NP levels and were not included in the
study cannot apparently speak against this because the PONTIAC
trial was not designed or powered to address this comparison (4).
Thus, why not follow a similar “intensiﬁed” and individualized
approach in all patients with DM? Cost analysis studies are
required to address whether such an approach is cost-effective.
Even in the ﬁeld of heart failure, where NPs are excellent
diagnostic and prognostic tools, there is still conﬂicting evidence
regarding their effectiveness to guide therapy; it seems that they
are of beneﬁt only when used in the context of a multidisciplinary
approach. Given that DM is currently considered a coronary artery
disease equivalent, the key to CV prevention in these patients
could be the close multidisciplinary follow-up, the individualization
of treatment, and the sufﬁcient use of health care resources. NPs or
other biomarkers may be of help as part of such an approach.Dimitrios Farmakis, MD
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We fully agree that the PONTIAC (NT-proBNP Guided Primary
Prevention of CV Events in Diabetic Patients) trial raises more
than a few new questions (1).
As mentioned by Dr. Farmakis and colleagues, most trials
conducted in patients with diabetes have been unsuccessful inreducing cardiovascular events. We agree that this might be based
at least in part on the wrong patient selection, which is an issue that
has been discussed before. The risk markers used in those studies
are inferior to N-terminal pro–B-type natriuretic peptide (NT-
proBNP), which was comprehensively proven prospectively (2,3)
and twice conﬁrmed recently.
In this context, we believe that we can learn even more from
the ROADMAP (Randomized Olmesartan and Diabetes Micro-
albuminuria Prevention) trial than from the points mentioned by
Dr. Farmakis and colleagues. The results of that trial were indeed
remarkable; the investigators found a delay in the worsening of
proteinuria not only at the cost of minor side effects such as hy-
potension but also with a small but signiﬁcant increase in fatal
cardiovascular events. The study was long withheld due to this
unexplainable result, similar to the REVIVE (Randomized Evalu-
ations of Levosimendan) study. We have to be aware that treatment
in low-risk patients might not only be inefﬁcient; oversuppression
of essential pathways (e.g., of the renin-angiotensin system [RAS])
can actually be harmful.
The second insight we have gained from the ROADMAP trial is
that the treatment of surrogates of outcome, such as proteinuria,
does not necessarily result in a survival beneﬁt. Others have already
called for not treating the marker but instead the system (4). This
has to be kept in mind when we interpret the unexpected lack
of a decrease in NT-proBNP levels, which was noted in the
PONTIAC and STOP-HF (St. Vincent’s Screening To Prevent
Heart Failure) trials (5). We did not intend to treat NT-proBNP,
but instead attempted to understand this marker primarily as a
surrogate for risk. The underlying cause of increased NT-proBNP
levels is not well understood. It can be assumed that activation of
the RAS and the adrenergic system are responsible for this phe-
nomenon. However, as noted by Dr. Farmakis and colleagues, a
decrease in kidney function might also be a possible reason. In this
case, an RAS antagonist would also be a valid treatment option.
Regarding risk, we believe there is no such thing as a false-positive
or negative result. Lower levels of NT-proBNP in highly-obese
people or increased levels in kidney disease directly translate into a
different risk proﬁle.
The concern that the effect of the PONTIAC trial is based
on care is probably not valid because the difference in the number
of visits only averaged 1.3. Unlike the STOP-HF trial, visits to our
treatment center did not lead to a change in diagnostic workup or
decisions about hospitalization, as stated in our report.
A decrease in glomerular ﬁltration rate after up-titration is a
common and clinically-negligible phenomenon, which has already
been extensively proven and discussed (6).
Finally, we agree that our results are not deﬁnitive. Further
studies are needed to prove whether our approach might be a way to
select patients who will beneﬁt from therapy.*Richard Pacher, MD
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